Authors: Måns Kadefors, Frida Berlin, Marie Wildt, Göran Dellgren, Sara Rolandsson Enes, Anders Aspberg, Gunilla Westergren-Thorsson

Journal: Frontiers in Pharmacology (2022)

Institution: Department of Experimental Medical Science, Sweden

Research Areas: Pharmacology

Cell Lines: Primary human lung fibroblasts

Summary: Dipeptidyl peptidase 4 (DPP4) has been proposed as a marker for activated fibroblasts in fibrotic disease. The study aimed to investigate whether a profibrotic DPP4 phenotype is present in lung tissue from patients with idiopathic pulmonary fibrosis (IPF). The authors observed a reduced frequency of primary DPP4+ fibroblasts in IPF tissue using flow cytometry and an absence of DPP4+ fibroblasts in pathohistological features of IPF. This study provided evidence that DPP4-expressing fibroblasts are not involved in IPF. As such, DPP4 targeted therapy in IPF is unlikely to have a direct effect on fibroblasts HoloMonitor M4 was used for cell morphology, cell proliferation and cell motility.

Keywords: HoloMonitor M4, cell morphology, cell proliferation, cell motility, fibroblast, lung, fibrosis, idiopathic pulmonary fibrosis, dipeptidyl peptidase 4